Business Context and Reporting Period
This Form 8-K Current Report from Immunic, Inc. (IMUX) covers events occurring between April 24, 2026, and April 28, 2026. The filing details significant changes to the company's executive leadership, specifically the appointment of a new Chief Medical Officer (CMO) and the resignation of the former CMO.
Key Financial Metrics and Compensation Details
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it discloses specific compensation figures related to executive employment agreements:
- New CMO Base Salary: $600,000 annually for Michael A. Panzara, M.D., M.P.H.
- New CMO Bonus: Target of at least 50% of base salary ($300,000).
- New CMO Signing Bonus: $125,000 total ($75,000 immediate, $50,000 after six months).
- New CMO Equity Grant: Options to purchase 300,000 shares of common stock.
- Former CMO Severance: 12 months of base salary plus 12 months of fixed annual salary from Immunic AG.
- Former CMO Consulting Retainer: $10,000 per month for up to 10 months.
Material Changes Versus Prior Period
The primary material change reported is the turnover of the Chief Medical Officer role:
- Appointment: Michael A. Panzara, M.D., M.P.H., was appointed CMO effective April 24, 2026. He previously served as CMO at Neurvati Neurosciences and Wave Life Sciences.
- Resignation: Andreas Muehler, M.D., M.B.A., resigned as CMO effective April 27, 2026. The filing states the resignation was not due to any disagreement with the company.
- Transition: Dr. Muehler transitioned to the title of Senior Medical Officer until April 30, 2026, and will serve as a consultant thereafter.
Outlook, Risks, and Unusual Items
Management Commentary and Transition: The Board expressed gratitude for Dr. Muehler's service. The company has structured a transition plan where Dr. Muehler will provide consulting services on an as-needed basis (up to 20 hours/month) for 10 months.
Severance and Equity Acceleration:
- Dr. Panzara: In the event of termination without cause or for "Good Reason," he is entitled to 12 months of severance and 100% acceleration of unvested equity. In a Change of Control scenario, severance increases to 18 months with full bonus acceleration.
- Dr. Muehler: Upon separation, 100% of his outstanding equity awards vested immediately. He has three years to exercise these awards.
Risks and Contingencies: The filing notes that receipt of severance benefits for both executives is conditioned upon the execution of a release of claims in favor of the Company.
Key Facts for Investor Verification
- Verify the impact of the CMO transition on the company's clinical development pipeline and ongoing trials.
- Confirm the total cash outflow for the new CMO's signing bonus and the former CMO's severance package in the upcoming quarters.
- Review the vesting schedule for Dr. Panzara's 300,000 share option grant (50% at one year, 50% over the subsequent 24 months).
- Monitor the company's cash burn rate given the immediate cash compensation obligations outlined in the employment and separation agreements.